Stocks · News reference
Independent Data and Safety Monitoring Board (DSMB) has recommended advancing the ongoing Phase 2 FREEDOM2-DM1 study evaluating PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) into the third and highest
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.29) by 10.34 percent. This is a 62.86 percent increase over losses of $(0.70) per share from the same
Read original at benzingaFiled: 2026-08-06 AccNo: 0001193125-26-336767 Size: 15 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgar